BNR
Burning Rock Biotech Limited
There isn't enough reported data to score BNR yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
BNR Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Unavailable |
BNR's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BNR PE Valuation
BNR has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BNR Forward outlook
There aren't enough analyst estimates for BNR to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
BNR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$9.65 | +$10.58 |
| Q1 2026 | -$8.45 | +$26.23 |
| Q4 2025 | -$7.77 | +$42.82 |
| Q3 2025 | -$17.38 | +$45.17 |
| Q2 2025 | -$20.23 | +$62.79 |
| Q1 2025 | -$34.68 | +$51.76 |
| Q4 2024 | -$50.59 | +$45.22 |
| Q3 2024 | -$62.55 | +$41.18 |
BNR is still losing money, but far less than before: $9.65 per share over the past year, against $216.37 at its worst in early 2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BNR on earnings quality, reporting a profit while its opponent remains loss making.
BNR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $20.2M | -9.2% |
| Q1 2026 | $16.2M | -19% |
| Q4 2025 | $19M | +0.2% |
| Q3 2025 | $19.8M | +2.3% |
| Q2 2025 | $22.3M | +9.6% |
| Q1 2025 | $20M | +5.9% |
| Q4 2024 | $18.9M | +4.1% |
| Q3 2024 | $19.3M | +0.8% |
BNR's revenue is shrinking: $20M last quarter, down 9.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -13% | -5.6 points |
| Q1 2026 | -17% | -6.1 points |
| Q4 2025 | -9.5% | +56 points |
| Q3 2025 | -12% | +18 points |
| Q2 2025 | -7.7% | +74 points |
| Q1 2025 | -11% | +89 points |
| Q4 2024 | -65% | +72 points |
| Q3 2024 | -30% | +110 points |
BNR's operating margin was −13% last quarter, down 5.6 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BNR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over BNR on profitability, with a higher operating margin.
BNR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.4M | +$3.3M |
| Q1 2026 | -$4.4M | -$867K |
| Q4 2025 | $2.7M | +30% |
| Q3 2025 | $2.5M | +$7M |
| Q2 2025 | -$6.7M | -$527.2K |
| Q1 2025 | -$3.5M | +$2.5M |
| Q4 2024 | $2M | +$5.7M |
| Q3 2024 | -$4.5M | +$2.6M |
BNR has burned cash in almost every quarter: −$3M over the past year, against −$13M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BNR on cash generation, producing positive trailing cash flow while its opponent burns cash.
BNR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.2% | +34.1K shares |
| 1 year | +0.9% | +9.2K shares |
| 3 years | +6% | +61.3K shares |
| 5 years | +4.3% | +45.2K shares |
| Available history | +369% | +854K shares |
BNR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $10,805 |
| Q3 2024 | — |
BNR hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BNR Net Leverage
BNR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
BNR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.4 | Neutral |
| Stochastic | 34.9 | Neutral |
BNR's weekly RSI is 50 (neutral) and its Stochastic is 35 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BNR PE vs Healthcare Sector
BNR has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BNR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.1 | 5.4% below |
| 20 week MA | $11.9 | 12% above |
| 50 week MA | $16.7 | 20% below |
| 100 week MA | $11.7 | 14% above |
| 200 week MA | $12.5 | 6.9% above |
BNR's trend is mixed: it's above three of its five weekly moving averages, and 6.9% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BNR on trend strength, trading above more of its moving averages.
BNR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $246.3 | $257.5 | +4.5% |
| 2021 | $257.5 | $105.0 | -59% |
| 2022 | $105.0 | $20.8 | -80% |
| 2023 | $20.8 | $9.30 | -55% |
| 2024 | $9.30 | $7.14 | -23% |
| 2025 | $7.14 | $21.2 | +197% |
| 2026 YTD | $21.2 | $13.3 | -37% |
BNR's yearly returns have swung widely, from +197% in 2025 to −80% in 2022. It's down 37% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BNR on returns for 2026, with the stronger performance.